Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
  • A61K9/0007—Effervescent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to a pharmaceutical composition containing as active ingredient the histamine H 2 -antagonist ranitidine, particularly a composition for oral administration.
• Ranitidine N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, and its physiologically acceptable salts are described and claimed in French Patent Specification No. 7724021, and a particular crystalline form of ranitidine hydrochloride is described and claimed in French Patent Specification No. 8118528.
• formulations for oral administration which may take the form of for example tablets, capsules, granules, powders, solutions, syrups, suspensions, or tablets or lozenges for buccal administration.
• Oral preparations of ranitidine are also disclosed in French Patent Specification No. 8407305.
• Ranitidine is a potent histamine H 2 -antagonist which, in the form of its hydrochloride salt, is widely used in the treatment of conditions where there is an advantage in lowering gastric acidity. Such conditions include duodenal and gastric ulceration, reflux oesophagitis and Zollinger-Ellison syndrome. Ranitidine may also be used prophylactically in surgical procedures, and in the treatment of allergic and inflammatory conditions where histamine is a known mediator.
• Oral administration constitutes a preferred route for administering ranitidine, and effervescent compositions provide a useful and advantageous type of formulation for oral use.
• an effervescent composition Prior to being taken by the patient, an effervescent composition is dissolved and/or dispersed in for example an aqueous medium, such as drinking water. Dissolution and/or dispersion takes place rapidly, with effervescence to give an agreeable presentation of the drug, particularly for patients who do not prefer to take tablets, or find difficulty in swallowing them.
• the solution or dispersion of the effervescent composition affords a liquid preparation containing a fixed dose of the drug, without any need for the patient to measure a prescribed volume.
• Effervescent compositions usually contain, in addition to the active ingredient, a source of carbon dioxide (such as an alkaline carbonate or bicarbonate) and an acid (such as citric acid).
• a source of carbon dioxide such as an alkaline carbonate or bicarbonate
• an acid such as citric acid
• the H 2 -antagonist ranitidine may be satisfactorily formulated as an effervescent composition, having the required degree of stability and a sufficiently rapid rate of dissolution, using a monoalkali metal citrate (more particularly monosodium citrate) alone.
• a monoalkali metal citrate more particularly monosodium citrate
• such effervescent compositions containing a monoalkali metal citrate alone are easier to manufacture than those containing a mixture of mono- and di-alkaline citrate.
• the present invention provides an effervescent pharmaceutical composition for oral use comprising ranitidine or a physiologically acceptable salt thereof, an alkali metal citrate, and an alkaline carbonate or bicarbonate, characterised in that the alkali metal citrate is solely a monoalkali metal citrate.
• the monoalkali metal citrate may be for example monopotassium citrate or, more preferably, monosodium citrate.
• the alkaline carbonate or bicarbonate may be for example an alkali metal (e.g. sodium or potassium) or an alkaline earth metal (e.g. magnesium or calcium) carbonate or bicarbonate, more preferably sodium bicarbonate.
• an alkali metal e.g. sodium or potassium
• an alkaline earth metal e.g. magnesium or calcium
• ranitidine should be employed in the composition according to the invention in the form of a physiologically acceptable salt.
• Such salts include salts of inorganic or organic acids such as hydrochloride, hydrobromide, sulphate, acetate, maleate, succinate, fumarate and ascorbate salts.
• Ranitidine in the form of a hydrochloride salt is particularly preferred.
• the amount of ranitidine, preferably in the form a physiologically acceptable salt, employed in the effervescent composition of the invention may be for example 50-600 mg, and will preferably be in the range of 50-500 mg, more preferably 150-300 mg, per dosage unit, expressed as the weight of free base.
• the ranitidine content of the effervescent composition (in the form of either free base or a physiologically acceptable salt) may be, for example, in the range of 2% to 30% on a weight-to-weight (w/w) basis.
• the monoalkali metal citrate and alkaline carbonate or bicarbonate may each independently constitute, for example 25% to 55% (w/w), more preferably 35% to 45% (w/w), of the effervescent composition.
• the ratio of monoalkali metal citrate to alkaline carbonate or bicarbonate may conveniently be within the range of 1:2 to 2:1, more preferably 1:1.
• a preferred effervescent composition according to the invention comprises ranitidine hydrochloride, monosodium citrate and sodium bicarbonate. More particularly, these three ingredients may be present in amounts of 2% to 30% (w/w), 25% to 55% (w/w) and 25% to 55% (w/w) respectively.
• the effervescent compositions according to the invention are particularly intended for use in human medicine.
• composition may be administered, for example, 1 to 4 times per day, preferably once or twice. It will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient.
• compositions may take the form of, for example, tablets, granules or powders, granules and powders conveniently being presented as a fixed dose in a sachet.
• the effervescent compositions according to the invention may be formulated using additional physiologically acceptable carriers or excipients as appropriate.
• additional carriers or excipients are preferably water soluble or substantially water soluble, and may be for example binding agents such as polyvinylpyrrolidone and/or lubricants such as siliconed sodium benzoate or polyalkylene glycols.
• Dye(s) may also be included.
• the effervescent composition When the effervescent composition is formulated as tablets, these preferably contain 1% to 2% (w/w) of a binding agent (e.g. polyvinylpyrrolidone) and 2% to 4% (w/w) of a lubricant (e.g. siliconed sodium benzoate).
• a binding agent e.g. polyvinylpyrrolidone
• a lubricant e.g. siliconed sodium benzoate
• the product When the effervescent composition is presented in a sachet, the product preferably contains 2% to 4% (w/w) of a binding agent (e.g. polyvinylpyrrolidone).
• tablets in particular may be larger than conventional tablets, and this permits the inclusion of other ingredients such as a suitable antacid e.g. aluminium hydroxide or magnesium hydroxide.
• a suitable antacid e.g. aluminium hydroxide or magnesium hydroxide.
• the composition may also contain flavouring and/or sweetening agents, which serve to mask the inherently bitter taste associated with ranitidine.
• Suitable flavouring agents may be for example lemon, orange, grapefruit or mint.
• the sweetening agents may be for example intense sweeteners (e.g. sodium saccharin, sodium cyclamate, aspartame, thaumatin or acesulfam K). Mixtures of sweetening and/or flavouring agents may also be used. The precise amount of sweetening and/or flavouring agent(s) will depend upon the nature of the agent(s) being used, but will be sufficient to mask the bitter taste associated with ranitidine.
• Effervescent compositions according to the invention have an adequate level of stability not only in the solid form, but also in the medium in which they are dispersed or dissolved by the patient.
• the effervescent compositions according to the invention may be prepared according to conventional techniques well known in the pharmaceutical industry for the manufacture of tablets, granules and powders. Such methods are very simple to operate, and can readily be reproduced on a manufacturing scale. They are also easy to control, and use starting materials which are readily available. This is in contrast to the preparation of effervescent compositions according to European Patent Specification No. 233853 where, before addition of the histamine H 2 -antagonist, it is necessary to prepare an effervescent ⁇ couple ⁇ by mixing stoichiometric quantities of citric acid and an alkaline carbonate or bicarbonate, and allowing these to react until the precise point is reached where monoalkaline citrate and dialkaline citrate are present in the desired ratio.
• the ranitidine or ranitidine salt, monoalkali metal citrate, and alkaline carbonate or bicarbonate may, for example, be blended with suitable excipients and, if desired, granulated. If the manufacturing process includes granulation, this should preceed the addition of any flavouring agent(s). Any sweetening agent(s) may be added either before or after granulation. Tablets may be prepared, for example, by compression of the powder blend or granulate, using a lubricant as an aid to tabletting.
• compositions according to the invention dissolve and/or disperse in water
• tablets may be packed individually in sealed strips made of a water-impervious material such as aluminium foil, or presented in suitable multidose containers (made of for example polypropylene) incorporating a dessicant (e.g. silica gel).
• a dessicant e.g. silica gel
• Powders or granules may for example be presented in sealed water-impervious sachets, conveniently containing a single fixed dose.
• compositions according to the invention in which the active ingredient is ranitidine hydrochloride.
• Ranitidine free base or other physiologically acceptable salts thereof may be formulated in a similar manner.
• Examples 1 to 5 illustrate effervescent tablets according to the invention.
• ranitidine hydrochloride, anhydrous monosodium citrate, sodium bicarbonate and saccharin sodium were mixed together, and granulated by the addition of a solution of the polyvinylpyrrolidone in the alcohol.
• the granules obtained after mixing were dried and passed through a calibrator, and the resulting granules were then mixed with the sodium benzoate and lemon flavouring.
• the granulated material was compressed into tablets using an alternative machine fitted with 20 mm punches.
• a rotative machine fitted with 20 mm punches may also be used for tabletting.
• the tablets were prepared as described in Example 1, but with the replacement of lemon flavour powder by orange and grapefruit flavouring.
• ranitidine hydrochloride, anhydrous monosodium citrate, sodium bicarbonate and saccharin sodium were mixed together, and granulated by the addition of a solution of the polyvinylpyrrolidone in the alcohol.
• the granules obtained after mixing were dried and passed through a calibrator, and the resulting granules were then mixed with the sodium benzoate and orange and grapefruit flavouring.
• the granulated material was compressed into tablets using an alternative machine fitted with 23 mm punches.
• the tablets were prepared as in Example 3, but with the use of mint flavouring instead of orange and grapefruit flavouring.
• an appropriate amount of sodium cyclamate for example 50-150 mg, preferably 80 mg in a 150 mg unit dose and 120 mg in a 300 mg unit dose
• aspartame for example 20-60 mg, preferably 30 mg, in a 150 mg unit dose; and 40-80 mg in a 300 mg unit dose
• sodium saccharin may replace sodium saccharin as the sweetener.
• ranitidine hydrochloride, anhydrous monosodium citrate, sodium bicarbonate and aspartame were mixed together, and granulated by the addition of a solution of the polyvinylpyrrolidone in the alcohol.
• the granules obtained after mixing were dried and passed through a calibrator, and the resulting granules were then mixed with the sodium benzoate and lemon flavouring.
• the granulated material was compressed into tablets using an alternative machine fitted with 20 mm punches.
• a rotative machine fitted with 20 mm punches may also be used for tabletting.
• Examples 6 to 8 illustrate effervescent compositions according to the invention for a sachet presentation.
• the ingredients (apart from the flavour powder) were mixed and granulated, and the resulting granules passed through a calibrator, as described for the preparation of tablets in Examples 1 to 5 above.
• the granules obtained were mixed with the flavouring, and the resulting mix was filled into sachets, 1.5 g for a 150 mg. unit dose of ranitidine, and 3.0 g for a 300 mg. unit dose of ranitidine (unit doses expressed as the weight of free base).
• the flavour powder may be lemon or a mixture of orange and grapefruit.
• the ingredients (apart from the flavour powder) were mixed and granulated, and the resulting granules passed through a calibrator, as described for the preparation of tablets in Examples 1 to 5 above.
• the granules obtained were mixed with the lemon flavouring, and the resulting mix was filled into sachets in 1.5 g portions, giving a 150 mg. unit dose of ranitidine (expressed as the weight of free base).
• the lemon flavouring may be replaced by an appropriate amount of a mixture of orange and grapefruit flavour powder.
• the ingredients (apart from the flavour powder) were mixed and granulated, and the resulting granules passed through a calibrator, as described for the preparation of tablets in Examples 1 to 5 above.
• the granules obtained were mixed with the orange and grapefruit flavouring, and the resulting mix was filled into sachets in 3.0 g portions, giving a 300 mg. unit dose of ranitidine (expressed as the weight of free base).
• orange and grapefruit flavouring may be replaced by an appropirate amount of lemon flavour powder.
• an appropriate amount of sodium cyclamate or aspartame may replace sodium saccharin as the sweetener (as described in connection with tablet Examples 1 to 4).

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Parent Applications (1)

Publications (1)

Family

ID=9367671

Family Applications (1)

Country Status (32)

Cited By (25)

Families Citing this family (7)

Citations (4)

Family Cites Families (1)

• 1988
  • 1988-06-24 FR FR8808497A patent/FR2633181B1/fr not_active Expired - Lifetime
• 1989
  • 1989-06-16 CH CH2263/89A patent/CH679276A5/fr not_active IP Right Cessation
  • 1989-06-22 LU LU87541A patent/LU87541A1/fr unknown
  • 1989-06-22 IT IT8948116A patent/IT1232149B/it active
  • 1989-06-22 SE SE8902288A patent/SE502285C2/sv not_active IP Right Cessation
  • 1989-06-23 MY MYPI89000847A patent/MY106412A/en unknown
  • 1989-06-23 BE BE8900692A patent/BE1005691A4/fr not_active IP Right Cessation
  • 1989-06-23 IL IL9073189A patent/IL90731A/en unknown
  • 1989-06-23 AT AT0154489A patent/AT396426B/de not_active IP Right Cessation
  • 1989-06-23 DK DK314089A patent/DK170223B1/da not_active IP Right Cessation
  • 1989-06-23 NL NL8901596A patent/NL8901596A/nl active Search and Examination
  • 1989-06-23 GB GB8914428A patent/GB2219940B/en not_active Expired - Lifetime
  • 1989-06-23 ES ES8902216A patent/ES2015717A6/es not_active Expired - Lifetime
  • 1989-06-23 JP JP1162481A patent/JPH0786086B2/ja not_active Expired - Lifetime
  • 1989-06-23 CA CA000603814A patent/CA1329130C/en not_active Expired - Lifetime
  • 1989-06-23 KR KR1019890008706A patent/KR940002662B1/ko not_active IP Right Cessation
  • 1989-06-23 ZW ZW78/89A patent/ZW7889A1/xx unknown
  • 1989-06-23 IE IE204789A patent/IE60725B1/en not_active IP Right Cessation
  • 1989-06-23 DE DE3920626A patent/DE3920626C2/de not_active Revoked
  • 1989-06-23 PH PH38837A patent/PH26018A/en unknown
  • 1989-06-23 ZA ZA894787A patent/ZA894787B/xx unknown
  • 1989-06-23 PT PT90962A patent/PT90962B/pt not_active IP Right Cessation
  • 1989-06-23 AU AU36744/89A patent/AU627194B2/en not_active Expired
  • 1989-06-23 NZ NZ229698A patent/NZ229698A/en unknown
• 1990
  • 1990-01-29 SA SA90100095A patent/SA90100095B1/ar unknown
• 1991
  • 1991-03-07 US US07/666,102 patent/US5102665A/en not_active Expired - Lifetime
  • 1991-12-23 SK SK4038-91A patent/SK403891A3/sk unknown
  • 1991-12-23 CZ CS914038A patent/CZ280886B6/cs not_active IP Right Cessation
• 1992
  • 1992-03-04 SG SG218/92A patent/SG21892G/en unknown
  • 1992-05-07 HK HK331/92A patent/HK33192A/xx not_active IP Right Cessation
  • 1992-11-06 CY CY1637A patent/CY1637A/xx unknown
• 1994
  • 1994-07-01 HU HU94P/P00002P patent/HU210067A9/hu unknown

Patent Citations (7)

Also Published As

Similar Documents

Legal Events